采用抗人胸腺细胞球蛋白（ATGAM）联合或不联合HLA单倍型相合骨髓输注治疗重型再生障碍性贫血。
Therapy of severe aplastic anemia with anti-human thymocyte globulin (ATGAM) with and without HLA-haploidentical bone-marrow infusion.
作者信息
Kim K Y
机构信息
Department of Pediatrics, Yonsei University, College of Medicine Seoul, Korea.
出版信息
J Korean Med Sci. 1986 Sep;1(1):37-41. doi: 10.3346/jkms.1986.1.1.37.
Six patients with severe aplastic anemia treated with horse anti-human thymocyte globulin (ATG) and androgen. Four of these patients were only given ATG (ATGAMR), 16 mg/Kg/dose x 10 doses. The remaining two cases received an infusion of maternal HLA-haploidentical marrow cells following ATG therapy. One patient had a complete response, three had a partial response, one showed minimal improvement and two were non-responders. The two patients who received the additional haploidentical marrow cells showed a hematologic recovery sooner than the ATG alone cases. The toxicity of the ATG therapy was tolerable. Long term follow up of there patients and further studies of this treatment in aplastic anemia with pediatric age group are under way.
6例重型再生障碍性贫血患者接受了马抗人胸腺细胞球蛋白（ATG）和雄激素治疗。其中4例患者仅接受了ATG（ATGAMR）治疗，剂量为16mg/kg/剂量，共10剂。其余2例患者在ATG治疗后接受了母亲单倍型相合骨髓细胞输注。1例患者完全缓解，3例部分缓解，1例有轻微改善，2例无反应。接受额外单倍型相合骨髓细胞的2例患者血液学恢复比单纯接受ATG治疗的患者更快。ATG治疗的毒性是可耐受的。目前正在对这些患者进行长期随访，并在儿童年龄组的再生障碍性贫血中对该治疗进行进一步研究。
Zotero 插件